| A multicenter, prospective randomized phase
III study to compare efficacy and safety of high dose immunoablation and autologous
hematopoietic stem cell transplantation with intravenous pulse therapy
cyclophosphamide for the treatment of patients with severe systemic sclerosis. |
|
| Principal
Investigators: Study Administration:
Email:
Study Chair:
|
EBMT/EULAR
SCLERODERMA STUDY GROUP
S Hales, Academic Centre Room 12B09, James Cook University Hospital, Marton Road, Middlesbrough, Teesside, TS4 3BW , UK. Tel: +44 1642 282498 Fax: +44 1642 28286
J.M. van Laar, Musculoskeletal Research Group, Institute of Cellular
Medicine, School of Clinical Medical Sciences, Newcastle University,
Newcastle upon Tyne, United Kingdom. Tel. 44 - 191 - 222 7139, Fax: +44 -
191 - 222 5455
D. Farge, Dept. of Internal Medicine, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, F-75475 Paris Cédex 10, France. Tel: 33 – 1 – 42 499768, Fax: 33 – 1- 2 499478,
A.Tyndall, Dept. of Rheumatology, Felix-Platter Spital, Burgfelder Strasse 101, 4055 Basel, Switzerland. Tel: 41 – 61 – 3264003, Fax: 41 – 61 –3264010, E-mail: alan.tyndall@fps-basel.ch
|
| Writing Committee:
Statistical Analysis:
Data Management: |
J.M. van Laar (Newcastle upon
Tyne), D. Farge (Paris), A. Tyndall (Basel), J.K.
Sont (Leiden), A. Gratwohl (Basel), H.H. Peter (Freiburg), F.H.J. van den Hoogen
(Nijmegen), W.E. Fibbe (Leiden)
S Hales (Middlesbrough), J.K. Sont (Leiden) |
Home | News | Protocol | Side Studies | Patient Info | Meetings | Participating Centers | Members | Links |
|
This page is maintained by Dr J.K. Sont, E-mail Last change: 11 July 2008 |
|